دورية أكاديمية
Prognostic Value and Clinical Significance of FGFR Genomic Alterations (GAs) in Metastatic Urothelial Cancer Patients.
| العنوان: | Prognostic Value and Clinical Significance of FGFR Genomic Alterations (GAs) in Metastatic Urothelial Cancer Patients. |
|---|---|
| المؤلفون: | Sevillano Fernández, Elena, Madurga Lacalle, Rodrigo, Rodriguez Moreno, Juan Francisco, Barquín García, Arantzazu, Yagüe Fernández, Mónica, Navarro Alcaraz, Paloma, Barba Llacer, María, Quiralte Pulido, Miguel, García-Donás Jiménez, Jesús |
| بيانات النشر: | Journal of Clinical Medicine |
| سنة النشر: | 2022 |
| المجموعة: | Universidad Francisco de Vitoria: Depósito Digital FV (DDFV) |
| مصطلحات موضوعية: | Metastatic urothelial cancer |
| الوصف: | Fibroblast growth factor receptor (FGFR) genomic alterations (GAs) represent an actionable target, key to the pathogenesis of some urothelial cancers (UCs). Though FGFR GAs are common in noninvasive UC, little is known about their role in the metastatic(m) setting and response to therapy. This study aimed to assess the impact of FGFR alterations on sensitivity to systemic treatments and survival and to validate Bajorin’s and Bellmunt’s prognostic scores in mUC patients according to their FGFR status. We retrospectively analyzed data from 98 patients with tumor-sequenced UC who received treatment between January 2010 and December 2020. Up to 77 developed metastatic disease and were deemed the study population. Twenty-six showed FGFR GAs. A trend toward a better response to cisplatin and checkpoint inhibitors was suggested favoring FGFR GA tumors. FGFR GA patients who received an FGFR inhibitor as first-line had poorer responses compared with other options (20% vs. 68.4%, p = 0.0065). Median PFS was 6 vs. 5 months in the FGFR GA vs. FGFR WT cohort (p = 0.71). Median OS was significantly worse in the FGFR GA vs. FGFR WT cohort (16.2 vs. 31.9 months, p = 0.045). Multivariate analyses deemed FGFR GAs as a factor independently associated with the outcome (HR 2.59 (95% CI 1.21–5.55)). Bajorin’s model correctly predicted clinical outcomes in the whole study population but not in FGFR GA cases. FGFR GAs are a relevant biomarker in mUC that could condition the response to systemic therapy. New prognostic models, including this molecular determination, should be designed and validated. ; post-print ; 2300 KB |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 2077-0383 |
| العلاقة: | https://www.mdpi.com/2077-0383/11/15/4483Test; https://hdl.handle.net/10641/3344Test |
| DOI: | 10.3390/jcm11154483 |
| الإتاحة: | https://doi.org/10.3390/jcm11154483Test https://hdl.handle.net/10641/3344Test |
| حقوق: | Atribución-NoComercial-SinDerivadas 3.0 España ; http://creativecommons.org/licenses/by-nc-nd/3.0/esTest/ ; openAccess |
| رقم الانضمام: | edsbas.E4A4E4DE |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 20770383 |
|---|---|
| DOI: | 10.3390/jcm11154483 |